A practical reference on cjc-1295: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-25. Anything still debated is marked as such rather than presented as settled.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
== Examples == A number of herbal medicines are classified as aquaretics, for example common horsetail or common nettle leaves. Synthetic aquaretics are vasopressin receptor antagonists and include conivaptan, tolvaptan, demeclocycline, and mozavaptan (OPC-31260), as well as lithium. Conivaptan hydrochloride and tolvaptan have been approved by the FDA for treating syndrome of inappropriate antidiuretic hormone. Mozavaptan is approved in Japan.
When the difference between successive pK values is less than about four there is overlap between the pH range of existence of the species in equilibrium. The smaller the difference, the more the overlap. The case of citric acid is shown at the right; solutions of citric acid are buffered over the whole range of pH 2.5 to 7.5. According to Pauling's first rule, successive pK values of a given acid increase (pKa2 > pKa1). For oxyacids with more than one ionizable hydrogen on the same atom, the pKa values often increase by about 5 units for each proton removed, as in the example of phosphoric acid above. It can be seen in the table above that the second proton is removed from a negatively charged species. Since the proton carries a positive charge extra work is needed to remove it, which is why pKa2 is greater than pKa1. pKa3 is greater than pKa2 because there is further charge separation. When an exception to Pauling's rule is found, it indicates that a major change in structure is also occurring. In the case of VO+2(aq), the vanadium is octahedral, 6-coordinate, whereas vanadic acid is tetrahedral, 4-coordinate. This means that four "particles" are released with the first dissociation, but only two "particles" are released with the other dissociations, resulting in a much greater entropy contribution to the standard Gibbs free energy change for the first reaction than for the others.
== External links == Suttas Mahā Nidāna Sutta at dhammatalks.org SN 12.1: Paticca-samuppada-vibhanga Sutta SN 12.23: Upanisa Sutta, translation by Bhikkhu Thanissaro SN 12.23: Upanisa Sutta, translation and exposition by Bhikkhu Bodhi Commentaries Pratītyasamutpāda by Alawwe Anōmadassi Thero Dependent Origination: the Buddhist Law of Conditionality, by Prayudh Payutto Paticcasamuppada: Practical Dependent Origination, by Buddhadasa The Doctrine of Paticcasamuppada, U Than Daing A Discourse on Paticcasamuppada, Mahasi Sayadaw The Shape of Suffering: A study of Dependent Co-arising, Bhikkhu Thanissaro (2008) Educational Resources
Victor Logachev − concert producer Stepan Popov − concert producer Dave "Shirt" Nichols − concert audio mixer Nina Bell − negotiations Roman Geigert − camera Dmitri Shevelev − camera Anna Gogichaishvili − camera Alexei "Siid" Tsarev − camera, editing Dmitri Grekulov − camera Dima "Brain" Zvjagin − camera Kiril Chapligin − coordination Artem Butsenko − recording and sound post-production, editing Dmitri Makhov − chief production
Thereafter, the amount of carbon-14 in organic matter decreases according to decay processes that may also be independently cross-checked by other means (such as checking the carbon-14 in individual tree rings, for example).
Sources: en.wikipedia.org
== Further reading == Hagedorn, Henry H.; Kunkel, Joseph G. (1979). "Vitellogenin and Vitellin in Insects". Annual Review of Entomology. 24 (4): 475–505. doi:10.1146/annurev.en.24.010179.002355. Wheeler, Diana E.; Kawooya, John K. (1990). "Purification and characterization of honey bee vitellogenin". Archives of Insect Biochemistry and Physiology. 14 (4): 253–267. doi:10.1002/arch.940140405. PMID 2134180. "Vitellogenin Gene Expression in Male Fathead Minnow as an Indicator of Exposure to Endocrine Disrupting Chemicals (EDC) in an Aquatic Environment". EPA.gov. 2006. Amdam, G. V.; Norberg, K.; Omholt, S. W.; Kryger, P.; Lourenço, A. P.; Bitondi, M. M. G.; Simões, Z. L. P. (November 2005). "Higher vitellogenin concentrations in honey bee workers may be an adaptation to life in temperate climates". Insectes Sociaux. 52 (4): 316–319. doi:10.1007/s00040-005-0812-2. S2CID 25197924. Seehuus, S.-C.; Norberg, K.; Gimsa, U.; Krekling, T.; Amdam, G. V. (17 January 2006). "Reproductive protein protects functionally sterile honey bee workers from oxidative stress". Proceedings of the National Academy of Sciences. 103 (4): 962–7. doi:10.1073/pnas.0502681103. PMC 1347965. PMID 16418279. Nelson, C. Mindy; Ihle, Kate E; Fondrk, M. Kim; Page, Robert E; Amdam, Gro V; Chittka, Lars (6 March 2007). "The Gene vitellogenin Has Multiple Coordinating Effects on Social Organization". PLOS Biology. 5 (3): e62. doi:10.1371/journal.pbio.0050062. PMC 1808115. PMID 17341131. Corona, M.; Velarde, R. A.; Remolina, S.; Moran-Lauter, A.; Wang, Y.; Hughes, K. A.; Robinson, G. E. (16 April 2007).
=== Video games === Liches are prominent in the Might and Magic series of video games, appearing primarily as enemies, but also as playable characters in several installments. They are equally prevalent in the spin-off series Heroes of Might and Magic, where they appear in most installments as recruitable creatures, but also as heroes. One of the most prolific liches in New World Computing's old continuity was Sandro, appearing in many titles and referenced in many more. The primary antagonist of Heroes of Might and Magic III: Restoration of Erathia is also a lich: the former king of Erathia raised by necromancers. The Baldur's Gate series of video games includes several liches, as powerful but optional boss fights. Warcraft III and World of Warcraft: Wrath of the Lich King features the continent of Northrend, the realm of the eponymous Lich King and his undead minions. Arthas Menethil, also known as the Lich King, one of the most prominent antagonists in Warcraft lore, appears as a raid boss in the Wrath of the Lich King expansion, as well as a playable character in the crossover video game Heroes of the Storm. In the Dota series of video games, Lich is one of the playable heroes. In League of Legends, the champion Karthus embraced the gift of death and became a lich. In the video game Enter the Gungeon, a lich is the final boss located in Bullet Hell. In Dragon Age: The Veilguard, companion Emmrich Volkarin can become a lich.
== Discovery == German chemist Felix Ehrlich discovered isoleucine while studying the composition of beet-sugar molasses 1903. In 1907 Ehrlich carried out further studies on fibrin, egg albumin, gluten, and beef muscle in 1907. These studies verified the natural composition of isoleucine. Ehrlich published his own synthesis of isoleucine in 1908.
Prior to 2000, only seven film series had grossed over $1 billion at the box office: James Bond, Star Wars, Indiana Jones, Rocky, Batman, Jurassic Park, and Star Trek. Since the turn of the century, that number has increased to over a hundred. This is partly due to inflation and market growth, but it is also due to Hollywood's adoption of the franchise model: films that have built-in brand recognition such as being based on a well-known literary source or an established character. The methodology is based on the concept that films associated with things audiences are already familiar with can be more effectively marketed to them, and as such are known as "pre-sold" films within the industry. A franchise is typically defined to be at least two works derived from a common intellectual property. Traditionally, the work has a tautological relationship with the property, but this is not a prerequisite. An enduring staple of the franchise model is the concept of the crossover, which can be defined as "a story in which characters or concepts from two or more discrete texts or series of texts meet". A consequence of a crossover is that an intellectual property may be utilized by more than one franchise. For example, Batman v Superman: Dawn of Justice belongs to not only the Batman and Superman franchises, but also to the DC Extended Universe, which is a shared universe. A shared universe is a particular type of crossover where a number of characters from a wide range of fictional works wind up sharing a fictional world.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.